An unreleased draft plan would ensure that negotiated drug prices would apply not only to the government but to employers and insurers.

Executives expressed support for eliminating drug rebates, increasing price transparency and shifting to a more value-based pricing system.

Sudden presidential interest has lawmakers on both sides of the aisle expressing optimism about attacking the problem.

Lawmakers are digging in on investigations into high drug prices, but the pharma industry does not look to be very cooperative.

The president has tasked HHS secretary Alex Azar and DOL secretary Alex Acosta with working on a solution to surprise medical bills.

Three of the lawmakers who will lead the House next year as Congress focuses on skyrocketing drug costs are among the biggest recipients of campaign contributions from the pharmaceutical industry.

Both parties expect record-breaking fundraising for this year's 30 contested elections for state attorneys general.

Sen. McCain leaves behind his own health care legacy, seemingly driven less by his interest in health care policy than his disdain for bullies.